8-K filing — Tempest Therapeutics, Inc. (TPST)
Filed: 2026-10-20 AccNo: 0001213900-26-111026 Size: 246 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 8.01: Other Events
Stocks · News reference
Tempest Therapeutics Enters Into Exclusive Option Agreement To License Senlang's CD7-Targeted Lentiviral Vector Platform And Portfolio Of In Vivo CAR-T Product Candidates
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tempest Therapeutics Files Prospectus Registering Resale Of Up To 9,534,164 Shares Of Common Stock
Up to 9,534,164 Shares of Common Stock This prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus, referred to as the selling stockholders, of up to 9,534,164
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Joseph Pantginis maintains Tempest Therapeutics (NASDAQ:TPST) with a Buy and lowers the price target from $11 to $7.
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?
Shares of Tempest Therapeutics Inc (NASDAQ: TPST) are trading sharply higher Wednesday morning as investors respond positively to a strategic agreement expanding the company's next-generation cell therapy pipeline.